Sutro Biopharma, Inc. STRO 深 滬
等待開盤 02-05 09:30:00 美东时间
14.66
-0.170
-1.15%
華盛通- 最 高15.15
- 今 開14.81
- 成交量 9.76万股
- 最 低 13.50
- 昨 收 14.83
- 總市值 1.25亿
- 52周最高 19.45
- 市盈率 靜 --
- 換手率 1.15%
- 52周最低 5.231
- 委 比 91.39%
- 總股本 851.35万
- 歷史最高 283.00
- 量 比 1.06
- 振 幅 11.13%
- 歷史最低 5.231
- 每 手 1
- 風險率 3.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
Citizens Upgrades Sutro Biopharma to Market Outperform, Announces $23 Price Target
Citizens analyst Reni Benjamin upgrades Sutro Biopharma (NASDAQ:STRO) from Market Perform to Market Outperform and announces $23 price target.
01-20 18:25
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has...
2025-12-19 20:55
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Sutro Biopharma, Inc. (NASDAQ: STRO) has regained compliance with Nasdaq's minimum share price requirement under Rule 5450(a)(1) after maintaining an average closing price of at least $1.00 per share following its 1:10 reverse stock split on December 3, 2025. This brings the company back into compliance with Nasdaq listing standards.
2025-12-17 21:05
快讯 | Sutro Biopharma宣布根据纳斯达克上市规则5635(C)(4)授予诱导性股权激励
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-12-17 05:05
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sutro Biopharma granted stock options and RSUs to new non-executive employees as inducement material for employment, vesting over four years. These grants follow Nasdaq Listing Rule 5635(c)(4) and are part of Sutro’s 2021 Equity Inducement Plan. Sutro Biopharma specializes in next-generation antibody-drug conjugates (ADCs), leveraging a cell-free platform to improve drug exposure, reduce side effects, and target diverse tumor types. Their pipelin...
2025-12-16 21:05
Sutro Biopharma falls as it announces 1-for-10 reverse stock split
Sutro Biopharma (STRO) said on Monday that its board has approved a reverse stock split of the company's outstanding shares of common stock at a ratio of 1-for-10. Sutro’s common stock will begin tr...
2025-12-01 21:16
Sutro Biopharma Announces 1-For-10 Reverse Stock Split, Effective Dec. 3
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its Board of Directors
2025-12-01 21:04
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
Sutro Biopharma announced FDA clearance for its IND application for STRO-004, a potential best-in-class Tissue Factor ADC, and expects to dose the first patient before year-end. The company presented new preclinical data highlighting novel dual-payload ADCs designed to overcome resistance and delay progression. Sutro also reported $167.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025, with a cash runway exte...
2025-11-06 21:30
